Novel Targeted Lipid-Lowering Therapies

LDL reduction is shown, but cardiovascular risk reduction still needs to be proved for several new agents.

Currently, statins, ezetimibe, and monoclonal antibodies directed against PCSK9 reduce low-density lipoprotein (LDL) cholesterol and have shown improved cardiovascular outcomes in randomized, controlled trials. Recently, several novel agents have gained FDA approval, including inclisiran, bempedoic acid, and evinacumab, which have proved LDL reduction but not yet been shown to improve cardiovascular outcomes. The current review article provides a summary of their mechanisms, indications, and efficacy.

Inclisiran is a small, interfering RNA (siRNA) agent that inhibits PCSK9. Injected every 6 months, it has shown durable LDL reduction of approximately 50%. Inclisiran is currently FDA approved for adults with heterozygous familial hypercholeste…

Reviewing Author

Karol E. Watson, MD, PhD, FACC

Disclosures

Consultant/Advisory BoardBoehringer Ingelheim; Amgen; Novartis; Lilly; Amarin

Speaker’s BureauBoehringer Ingelheim

Grant/Research SupportNIH

Editorial BoardsCirculation (Associate Editor)